• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于描述治疗性单克隆 IgG 抗体在人体内处置的两孔最小生理基于药代动力学模型。

Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, BioPharm Building, Room 341, 789 S. Limestone, Lexington, Kentucky, 40536, USA.

出版信息

Pharm Res. 2018 Feb 6;35(3):47. doi: 10.1007/s11095-017-2292-2.

DOI:10.1007/s11095-017-2292-2
PMID:29411151
Abstract

PURPOSE

The aim of this study was to develop a two-pore minimum physiologically-based pharmacokinetic (mPBPK) model in describing the pharmacokinetic (PK) of therapeutic monoclonal antibody (TMAb) in human subjects.

METHODS

PK data used in this study were endogenous/exogenous native IgG and two TMAbs (palivizumab and Motavizumab-YTE) in normal volunteer or familial hypercatabolic hypoproteinemia (FIHH) patient. Several important components were implemented to overcome the limitations of the early mPBPK model, e.g. two-pore model to describe the transcapillary transport of IgG from vascular to interstitial space. Six mPBPK models with different osmotic reflection coefficient (OFC) of transcapillary transport, endocytosis rates (ETR) and plasma clearance for the TMAbs/IgG were tested and the best model was selected using AICc values.

RESULTS

The final model consisted of different OFC and ETR values for native IgG and TMAbs, supporting the hypothesis that the dynamics in the endosomal space had an important role in the compliant FcRn salvage mechanism to determine the clearance of TMAbs. The estimated FcRn concentration of FIHH subjects was 2.72 μmol/l. The final two-pore mPBPK model has a better performance for native IgG than previously developed mPBPK model.

CONCLUSIONS

The final two-pore mPBPK model not only overcome the limitations of the early mPBPK model but also has a better performance to describe the disposition of the IgG antibody in human subjects.

摘要

目的

本研究旨在开发一个双孔最小生理基于药代动力学(mPBPK)模型,以描述人受试者中治疗性单克隆抗体(TMAb)的药代动力学(PK)。

方法

本研究中使用的 PK 数据是内源性/外源性天然 IgG 和两种 TMAb(帕利珠单抗和莫替唑单抗-YTE)在正常志愿者或家族性高代谢性低蛋白血症(FIHH)患者中的数据。实施了几个重要的组件来克服早期 mPBPK 模型的局限性,例如双孔模型来描述 IgG 从血管到间质空间的跨毛细血管转运。测试了六个具有不同跨毛细血管转运渗透压反射系数(OFC)、内吞率(ETR)和 TMAb/IgG 血浆清除率的 mPBPK 模型,并使用 AICc 值选择最佳模型。

结果

最终模型由天然 IgG 和 TMAb 的不同 OFC 和 ETR 值组成,支持内体空间动力学在确定 TMAb 清除率的顺应性 FcRn 拯救机制中起重要作用的假设。FIHH 受试者的估计 FcRn 浓度为 2.72 μmol/L。最终的双孔 mPBPK 模型对天然 IgG 的性能优于先前开发的 mPBPK 模型。

结论

最终的双孔 mPBPK 模型不仅克服了早期 mPBPK 模型的局限性,而且对描述人受试者中 IgG 抗体的处置具有更好的性能。

相似文献

1
Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.用于描述治疗性单克隆 IgG 抗体在人体内处置的两孔最小生理基于药代动力学模型。
Pharm Res. 2018 Feb 6;35(3):47. doi: 10.1007/s11095-017-2292-2.
2
Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.最小生理药代动力学模型研究荷电荷对人源抗 HCV-E2 IgG 抗体在 Sprague-Dawley 大鼠体内药代动力学的影响。
Pharm Res. 2022 Mar;39(3):481-496. doi: 10.1007/s11095-022-03204-2. Epub 2022 Mar 4.
3
Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.应用最小生理药代动力学模型研究 FcRn 发育药理学对儿科受试者治疗性单克隆 IgG 抗体药代动力学的影响。
MAbs. 2018 Oct;10(7):1144-1156. doi: 10.1080/19420862.2018.1494479. Epub 2018 Jul 30.
4
Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.最小生理基于药代动力学模型研究 pH 依赖性 FcRn 亲和力和内皮细胞内吞作用对抗 VEGF 人源化 IgG1 抗体在食蟹猴体内药代动力学的影响。
Eur J Pharm Sci. 2018 Dec 1;125:130-141. doi: 10.1016/j.ejps.2018.09.015. Epub 2018 Sep 21.
5
Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.纳入FcRn介导的处置模型以描述临床患者中治疗性单克隆IgG抗体的群体药代动力学。
Biopharm Drug Dispos. 2016 Mar;37(2):107-19. doi: 10.1002/bdd.1997.
6
A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K, K, endosome trafficking, and animal species.一个最小的基于生理学的药代动力学模型,用于研究 FcRn 介导的单克隆抗体回收:K 的影响、K、内体转运和动物物种。
MAbs. 2018 Nov-Dec;10(8):1322-1331. doi: 10.1080/19420862.2018.1506648. Epub 2018 Sep 11.
7
Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.利用最小生理药代动力学模型对人体内单克隆抗体处置情况的研究。
J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):571-80. doi: 10.1007/s10928-014-9374-0. Epub 2014 Aug 22.
8
A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.一种具有嵌套内体隔室的最小生理基于药代动力学模型,用于新型工程抗体。
AAPS J. 2018 Mar 14;20(3):48. doi: 10.1208/s12248-017-0183-4.
9
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.使用最小生理药代动力学模型模拟单克隆抗体在人体内的药代动力学
AAPS J. 2014 Sep;16(5):1097-109. doi: 10.1208/s12248-014-9640-5. Epub 2014 Jul 9.
10
Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.开发和评价一种基于生理学的药代动力学模型,用于预测抗 FcRn 治疗对内源性 IgG 在人体内处置的影响。
J Pharm Sci. 2019 Jan;108(1):714-724. doi: 10.1016/j.xphs.2018.10.067. Epub 2018 Nov 22.

引用本文的文献

1
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.用于描述不同大小的内源性和外源性蛋白质在体内整体分布的双孔跨膜蛋白 PBPK 模型的转化。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):449-476. doi: 10.1007/s10928-024-09922-x. Epub 2024 May 1.
2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.研究抗体大小、电荷和与 FcRn/抗原结合亲和力对抗体药代动力学的综合影响的最小生理基于药代动力学模型。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):477-492. doi: 10.1007/s10928-023-09899-z. Epub 2024 Feb 24.
3

本文引用的文献

1
Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.治疗性蛋白质的生理药代动力学建模
J Pharm Sci. 2017 Sep;106(9):2270-2275. doi: 10.1016/j.xphs.2017.03.038. Epub 2017 Apr 7.
2
The role of patient-based treatment planning in peptide receptor radionuclide therapy.基于患者的治疗计划在肽受体放射性核素治疗中的作用。
Eur J Nucl Med Mol Imaging. 2016 May;43(5):871-880. doi: 10.1007/s00259-015-3248-6. Epub 2015 Nov 18.
3
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.
最小生理药代动力学模型研究荷电荷对人源抗 HCV-E2 IgG 抗体在 Sprague-Dawley 大鼠体内药代动力学的影响。
Pharm Res. 2022 Mar;39(3):481-496. doi: 10.1007/s11095-022-03204-2. Epub 2022 Mar 4.
4
Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.从临床前动物外推纳米材料的处置和药代动力学的研究工具。
Theranostics. 2019 May 18;9(11):3365-3387. doi: 10.7150/thno.34509. eCollection 2019.
5
Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.应用最小生理药代动力学模型研究 FcRn 发育药理学对儿科受试者治疗性单克隆 IgG 抗体药代动力学的影响。
MAbs. 2018 Oct;10(7):1144-1156. doi: 10.1080/19420862.2018.1494479. Epub 2018 Jul 30.
在不影响人源化单克隆抗体的等电点的情况下平衡互补决定区的电荷,可减少非特异性结合并改善药代动力学。
MAbs. 2015;7(3):483-93. doi: 10.1080/19420862.2015.1016696.
4
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.新生儿Fc受体(FcRn)以相同的亲和力独立结合至IgG同型二聚体的两个位点。
MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353.
5
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.pH 依赖性结合工程揭示了一个控制 IgG 循环的 FcRn 亲和力阈值。
J Biol Chem. 2015 Feb 13;290(7):4282-90. doi: 10.1074/jbc.M114.603712. Epub 2014 Dec 23.
6
Fc fusion as a platform technology: potential for modulating immunogenicity.Fc 融合作为一种平台技术:调节免疫原性的潜力。
Trends Biotechnol. 2015 Jan;33(1):27-34. doi: 10.1016/j.tibtech.2014.11.001. Epub 2014 Dec 6.
7
Physiologically based pharmacokinetic modeling and simulation in pediatric drug development.生理基于药代动力学模型在儿科药物开发中的应用与模拟。
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3(11):e150. doi: 10.1038/psp.2014.45.
8
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.使用最小生理药代动力学模型模拟单克隆抗体在人体内的药代动力学
AAPS J. 2014 Sep;16(5):1097-109. doi: 10.1208/s12248-014-9640-5. Epub 2014 Jul 9.
9
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.一种新型的研究性Fc修饰人源化单克隆抗体莫他维izumab-YTE在健康成年人中具有延长的半衰期。
Antimicrob Agents Chemother. 2013 Dec;57(12):6147-53. doi: 10.1128/AAC.01285-13. Epub 2013 Sep 30.
10
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?内体运输参数是否比 FcRn 结合亲和力更能成为改善单抗药代动力学的目标?
Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2.